PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
0.06 - 0.07
0.06 - 0.24
1.89M / 3.59M (Avg.)
-1.60 | -0.04
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-59.30%
Both face negative 5Y revenue/share CAGR. Martin Whitman would suspect macro headwinds or obsolete product offerings across the niche.
-30.20%
Negative 3Y CAGR while CRN.AX stands at 62.82%. Joel Greenblatt would look for missteps or fading competitiveness that hurt sales.
94.58%
OCF/share CAGR of 94.58% while CRN.AX is zero. Bruce Berkowitz might see a slight advantage that could compound over time.
-105.84%
Both show negative mid-term OCF/share growth. Martin Whitman might suspect a challenged environment or large capital demands for both.
88.82%
3Y OCF/share CAGR above 1.5x CRN.AX's 28.67%. David Dodd would confirm if the firm is quickly gaining an operational edge over the competitor.
121.88%
10Y net income/share CAGR of 121.88% while CRN.AX is zero. Bruce Berkowitz would see if minor gains can compound into a bigger lead over time.
377.12%
Positive 5Y CAGR while CRN.AX is negative. John Neff might view this as a strong mid-term relative advantage.
149.43%
3Y net income/share CAGR 75-90% of CRN.AX's 184.12%. Bill Ackman might push for an operational plan to match or beat the competitor’s short-term growth.
-87.09%
Negative equity/share CAGR over 10 years while CRN.AX stands at 0.00%. Joel Greenblatt sees a fundamental red flag unless the competitor also struggles.
105.50%
Positive 5Y equity/share CAGR while CRN.AX is negative. John Neff might see a clear edge in retaining earnings or managing capital better.
539.08%
3Y equity/share CAGR above 1.5x CRN.AX's 57.34%. David Dodd verifies the company’s short-term capital management far exceeds the competitor’s pace.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.